Comparative Pharmacology
Head-to-head clinical analysis: DEXACORT versus ORALONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACORT versus ORALONE.
DEXACORT vs ORALONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
ORALONE is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory cytokines.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
0.3-0.6 mg/kg IV/IM every 4-6 hours as needed; maximum single dose 30 mg.
None Documented
None Documented
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
1.5–3 hours (mean 2.5 hours) in adults; prolonged to 3–6 hours in hepatic impairment and up to 4 hours in elderly patients.
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Renal: >90% as glucuronide conjugates and unchanged drug (approximately 60% as metabolites, 30% unchanged). Biliary/fecal: <5%.
Category C
Category C
Corticosteroid
Corticosteroid